Relmada Therapeutics Inc (RLMD) Stock Price, Quote & News

Company Profile

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 786 629 1376

Website: www.relmada.com

Address:

2222 Ponce de Leon Blvd., Floor 3, Coral Gables, United States

Equibles Sep. 18 at 4:08 AM

$RLMD This one turned up on Equibles. Relmada Therapeutics, Inc. Chief Executive Officer TRAVERSA SERGIO reported buying 100,000 RLMD shares on September 10, 2026, worth about $410 thousand, in a non-derivative Form 4.

0 · Reply

Form4Alerts Sep. 13 at 9:54 PM

$RLMD — Chief Executive Officer Sergio Traversa bought $828K · Chief Financial Officer Maged Shenouda bought $844K alongside them. · 2 insiders have bought $1.67M here in the last 1 days. · Chief executive — buying their own company. Insider grade: A (from their own prior trades) Not investment advice.

0 · Reply

MingChoo Sep. 13 at 8:54 PM

$RLMD Bullish.h

0 · Reply

CEOBuysDisclosures Sep. 11 at 1:35 PM

$RLMD CEO purchased 200,000 shares at $4.14 for a total of $828,000. TRAVERSA SERGIO now owns 1,500,000 shares. https://ceo-buys.com

0 · Reply

SannieVerraderlijk Sep. 11 at 11:49 AM

$RLMD 1.6M insider buying CEO + CFO https://x.com/BOSSTRADING0/status/2098376353603035262?s=20

0 · Reply

SannieVerraderlijk Sep. 9 at 11:39 AM

$TYRA Underwhelmed, can we pump my $RLMD bags now?

0 · Reply

VolcanicTrades Aug. 11 at 11:49 PM

$RLMD lot of bio stocks curling up….$BEAT $ONCO $GLMD

0 · Reply

teaman60 Aug. 7 at 11:16 AM

$RLMD I was right

1 · Reply

StocktwitsEarnings Aug. 6 at 10:04 PM

$RLMD Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.11 up 63.33% YoY

0 · Reply

EarningsInsider Aug. 6 at 9:22 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript

0 · Reply

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

2026-08-06T21:35:46.000Z - 6 weeks ago

Relmada Therapeutics reports Q2 EPS (11c), consensus (20c)

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Relmada Therapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Relmada Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 6 weeks ago

Relmada Therapeutics Earnings release: Q2 2026

2026-07-28T13:20:34.000Z - 7 weeks ago

Relmada Therapeutics appoints Bipin Dalmia as chief business officer

2026-07-28T13:15:20.000Z - 7 weeks ago

Relmada Therapeutics names Bipin Dalmia chief business officer

Jul 28, 2026, 8:30 AM EDT - 7 weeks ago

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Jul 16, 2026, 7:05 AM EDT - 2 months ago

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

2026-06-29T11:10:10.000Z - 2 months ago

Relmada Therapeutics joins Russell 2000, Russell 3000 Indexes

Jun 29, 2026, 7:00 AM EDT - 2 months ago

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

2026-06-18T10:07:12.000Z - 3 months ago

Relmada Therapeutics initiated with a Buy at H.C. Wainwright

Jun 11, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program

Jun 9, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics Slides: Corporate presentation

Jun 4, 2026, 12:50 PM EDT - 3 months ago

Relmada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 7:00 AM EDT - 3 months ago

Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

May 27, 2026, 9:30 AM EDT - 3 months ago

Relmada Therapeutics Transcript: AGM 2026

2026-05-13T21:24:00.000Z - 4 months ago

Relmada Therapeutics files automatic mixed securities shelf

May 12, 2026, 4:30 PM EDT - 4 months ago

Relmada Therapeutics Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

Relmada Therapeutics Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 4 months ago

Relmada Therapeutics Earnings release: Q1 2026

May 12, 2026, 4:05 PM EDT - 4 months ago

Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 7:00 AM EDT - 4 months ago

Relmada Therapeutics Slides: Company presentation

May 12, 2026, 7:00 AM EDT - 4 months ago

Relmada Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 4 months ago

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

May 5, 2026, 7:00 AM EDT - 4 months ago

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Relmada Therapeutics Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 5 months ago

Relmada Therapeutics Registration statement: Registration filing

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Relmada Therapeutics Slides: Corporate presentation

2026-03-24T09:00:12.000Z - 6 months ago

Relmada Therapeutics initiated with an Overweight at Piper Sandler

2026-03-20T11:37:53.000Z - 6 months ago

Relmada Therapeutics price target raised to $19 from $10 at Mizuho

Mar 19, 2026, 4:30 PM EDT - 6 months ago

Relmada Therapeutics Earnings Call Transcript: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 6 months ago

Relmada Therapeutics Annual report: Q4 2025

Mar 19, 2026, 4:30 PM EDT - 6 months ago

Relmada Therapeutics Earnings release: Q4 2025

Mar 19, 2026, 4:01 PM EDT - 6 months ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Mar 19, 2026, 7:00 AM EDT - 6 months ago

Relmada Therapeutics Slides: Study Result Presentation

Mar 19, 2026, 7:00 AM EDT - 6 months ago

Relmada Therapeutics Slides: Corporate presentation

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Mar 10, 2026, 8:40 AM EDT - 6 months ago

Relmada Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:30 PM EDT - 6 months ago

Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference

2026-03-09T12:00:38.000Z - 6 months ago

Why Is Relmada Therapeutics Stock (RLMD) Up Today?

2026-03-09T11:30:59.000Z - 6 months ago

Relmada Therapeutics prices 29.47M shares at $4.75 in private placement

2026-03-09T11:15:52.000Z - 6 months ago

Relmada Therapeutics reports 12-month Phase 2 interim data for NDV-01

Mar 9, 2026, 7:05 AM EDT - 6 months ago

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Mar 9, 2026, 7:00 AM EDT - 6 months ago

Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer

2026-03-02T11:38:48.000Z - 6 months ago

Relmada Therapeutics initiated with a Buy at Lucid Capital

2026-01-23T11:25:12.000Z - 8 months ago

Relmada Therapeutics assumed at Outperform from Market Perform at Leerink

2026-01-12T12:16:48.000Z - 8 months ago

Relmada Therapeutics provides regulatory update on FDA alignment for NDV-01

Jan 12, 2026, 7:00 AM EST - 8 months ago

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

2025-12-22T00:10:11.000Z - 9 months ago

Relmada Therapeutics initiated with a Buy at Jefferies

2025-12-03T12:35:52.000Z - 9 months ago

Relmada Therapeutics to present NDV-01 Phase 2 data at SUO meeting

Dec 3, 2025, 7:30 AM EST - 9 months ago

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

2025-11-19T13:40:55.000Z - 10 months ago

Mizuho upgrades Relmada to Outperform with ‘more upside’ ahead

Nov 14, 2025, 6:00 AM EST - 10 months ago

Relmada Therapeutics Slides: Investor presentation

Nov 13, 2025, 4:30 PM EST - 10 months ago

Relmada Therapeutics Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Relmada Therapeutics Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 10 months ago

Relmada Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:01 PM EST - 10 months ago

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Nov 7, 2025, 7:30 AM EST - 10 months ago

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Nov 4, 2025, 7:09 AM EST - 10 months ago

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Nov 4, 2025, 7:01 AM EST - 10 months ago

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Oct 7, 2025, 7:30 AM EDT - 11 months ago

Relmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01

Sep 18, 2025, 10:00 AM EDT - 1 year ago

Relmada Therapeutics Transcript: Small-Cap Virtual Conference

Sep 16, 2025, 9:00 AM EDT - 1 year ago

Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 10, 2025, 7:15 AM EDT - 1 year ago

Relmada Issues Mid-Year CEO Letter to Shareholders

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

Jul 31, 2025, 7:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Jul 9, 2025, 8:00 AM EDT - 1 year ago

DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Transcript: Status Update

Apr 28, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Press release: Status Update

Apr 28, 2025, 1:38 PM EDT - 1 year ago

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

Apr 27, 2025, 9:00 AM EDT - 1 year ago

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics To Present NDV-01 Data at AUA2025

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Relmada Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Annual report: Q4 2024

Mar 27, 2025, 4:30 PM EDT - 1 year ago

Relmada Therapeutics Earnings release: Q4 2024

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 26, 2025, 9:00 AM EDT - 1 year ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

Feb 6, 2025, 7:30 AM EST - 1 year ago

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

Dec 9, 2024, 8:11 AM EST - 1 year ago

Relmada discontinues late-stage trials for depression drug, explores sale

Dec 9, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

Dec 4, 2024, 8:00 AM EST - 1 year ago

Relmada's depression drug unlikely to meet main trial goal, analysis shows

Dec 4, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

Nov 21, 2024, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Nov 20, 2024, 7:00 AM EST - 1 year ago

Relmada Therapeutics Transcript: Jefferies London Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 1 year ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

Nov 7, 2024, 4:32 PM EST - 1 year ago

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics Quarterly report: Q3 2024

Nov 4, 2024, 4:30 PM EST - 1 year ago

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Relmada Therapeutics Registration statement: Registration Filing

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Relmada Therapeutics Earnings release: Q2 2024

Aug 7, 2024, 4:05 PM EDT - 2 years ago

Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:30 AM EDT - 2 years ago

Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024

Equibles Sep. 18 at 4:08 AM

0 · Reply

Form4Alerts Sep. 13 at 9:54 PM

0 · Reply

MingChoo Sep. 13 at 8:54 PM

$RLMD Bullish.h

0 · Reply

CEOBuysDisclosures Sep. 11 at 1:35 PM

$RLMD CEO purchased 200,000 shares at $4.14 for a total of $828,000. TRAVERSA SERGIO now owns 1,500,000 shares. https://ceo-buys.com

0 · Reply

SannieVerraderlijk Sep. 11 at 11:49 AM

$RLMD 1.6M insider buying CEO + CFO https://x.com/BOSSTRADING0/status/2098376353603035262?s=20

0 · Reply

SannieVerraderlijk Sep. 9 at 11:39 AM

$TYRA Underwhelmed, can we pump my $RLMD bags now?

0 · Reply

VolcanicTrades Aug. 11 at 11:49 PM

$RLMD lot of bio stocks curling up….$BEAT $ONCO $GLMD

0 · Reply

teaman60 Aug. 7 at 11:16 AM

$RLMD I was right

1 · Reply

StocktwitsEarnings Aug. 6 at 10:04 PM

$RLMD Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.11 up 63.33% YoY

0 · Reply

EarningsInsider Aug. 6 at 9:22 PM

https://www.marketbeat.com/earnings/reports/2026-8-6-relmada-therapeutics-inc-stock/ $RLMD Relmada Therapeutics Earnings Transcript

0 · Reply

teaman60 Aug. 5 at 1:59 AM

$RLMD Well we have passed the time when they said test results would be released so I am not expecting good news on this.

1 · Reply

Quantumup Jul. 31 at 12:21 PM

$NBIX Baird-OP⬆️$225 was$186 Stifel-Buy⬆️$215 was$188 SLNO $RYTM $RLMD HRMY Needham-Buy⬆️$204 was$200~continue2see meaningful NBIX upside—driven by an established Ingrezza franchise—2 add'l growth products—well funded pipeline—w/ multiple data readouts '27+ Guggenheim-Buy⬆️$222 was $200; Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2083165891739390434?s=20

0 · Reply